Aciont® Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive, controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance.

One revolutionary aspect of our technology platform is the incorporation of a novel sustained release methodology for water soluble or poorly soluble drugs (commonly susceptible to ocular clearance effects) as part of a non-invasive or topical drug delivery system. Visulex’s passive diffusion-based sustained release system has demonstrated superior pharmacokinetic profiles over other technologies that deliver water soluble and poorly soluble agents passively and actively (iontophoresis) to the posterior pole of the eye and has been shown to treat retinal disease under a known preclinical model using a variety of proprietary pharmaceutical formulations and methods. Many of the leading back of the eye drug delivery technologies are invasive in nature because they target the eye’s interior regions such as the vitreous or retina, which often cannot be reached via conventional methods (e.g., eye drops).